Evidence map›Paper›PMID 28669118›Full record

ReviewJournal of neurology2017

Quantifying fat replacement of muscle by quantitative MRI in muscular dystrophy.

Jedrzej Burakiewicz, Christopher D J Sinclair, Dirk Fischer, Glenn A Walter, Hermien E Kan, Kieren G Hollingsworth

2 registry-linked trialsOpen access · hybridAbstract readReview
In one paragraph

Review in Journal of neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 131 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 1 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05618080 active not recruitingnot on this mapstarted 2024, after this paper: background citation

GRASP-01-003: Trial Readiness and Endpoint Assessment in LGMD R1

TypeobservationalSponsorVirginia Commonwealth UniversityRan2024 to 2028Enrolled100ConditionsCalpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A, Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type R1, LGMD2A
NCT05989620 recruitingnot on this mapstarted 2023, after this paper: background citation

Long-Term Development of Muscular Dystrophy Outcome Assessments (GRASP-01-005)

TypeobservationalSponsorVirginia Commonwealth UniversityRan2023 to 2029Enrolled1,000ConditionsLGMD1B, LGMD1C, LGMD1D, LGMD1E
3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 1 synthesis or guideline pooled it, 217 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Degeneration of paraspinal and gluteus medius muscles in nonspecific chronic low back pain: a quantitative MRI study.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026
    Article
  18. Mapping glycogen accumulation and treatment effect in Pompe disease with saturation transfer MRI.Translational research : the journal of laboratory and clinical medicine · 2026
    Article
  19. Article
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 5 countries.

Jedrzej BurakiewiczDepartment of Radiology, C. J. Gorter Center for High Field MRI, Leiden University Medical Centre, Leiden, The Netherlands.
Christopher D J SinclairMRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, UK.
Dirk FischerDivision of Neuropaediatrics, University of Basel Children's Hospital, Spitalstrasse 33, Postfach, Basel, 4031, Switzerland.
Glenn A WalterDepartment of Physiology and Functional Genomics, University of Florida, Gainesville, FL, 32610, USA.
Hermien E KanDepartment of Radiology, C. J. Gorter Center for High Field MRI, Leiden University Medical Centre, Leiden, The Netherlands.
Kieren G HollingsworthNewcastle Magnetic Resonance Centre, Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK. kieren.hollingsworth@newcastle.ac.uk.
Leiden University Medical Center · NLMRC Prion Unit · GBNewcastle University · GBUniversity of Basel · CHUniversity of Florida · US

Funding

European Union COST BM1304 (MYO-MRI)Medical Research Council G1100160
6 · The paper itself

Abstract

The muscular dystrophies are rare orphan diseases, characterized by progressive muscle weakness: the most common and well known is Duchenne muscular dystrophy which affects young boys and progresses quickly during childhood. However, over 70 distinct variants have been identified to date, with different rates of progression, implications for morbidity, mortality, and quality of life. There are presently no curative therapies for these diseases, but a range of potential therapies are presently reaching the stage of multi-centre, multi-national first-in-man clinical trials. There is a need for sensitive, objective end-points to assess the efficacy of the proposed therapies. Present clinical measurements are often too dependent on patient effort or motivation, and lack sensitivity to small changes, or are invasive. Quantitative MRI to measure the fat replacement of skeletal muscle by either chemical shift imaging methods (Dixon or IDEAL) or spectroscopy has been demonstrated to provide such a sensitive, objective end-point in a number of studies. This review considers the importance of the outcome measures, discusses the considerations required to make robust measurements and appropriate quality assurance measures, and draws together the existing literature for cross-sectional and longitudinal cohort studies using these methods in muscular dystrophy.

Indexed as

Adipose TissueHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMuscle, SkeletalMuscular DystrophiesClinical trialDuchenneMRIMuscleMuscular dystrophyQuantitative

Identifiers

PMID28669118
PMCPMC5617883
OpenAlexW2724098443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.